Comparative effectiveness and safety of prasugrel and ticagrelor in patients of acute coronary syndrome undergoing percutaneous transluminal coronary angioplasty: A propensity score-matched analysis

• Published in: Indian heart journal Vol. 76; no. 2; pp. 133 - 135
• Main Authors: Ray, Avik, Najmi, Ahmad, Khandelwal, Gaurav, Jhaj, Ratinder, Sadasivam, Balakrishnan
• Format: Journal Article
• Language: English
• Published: India Elsevier, a division of RELX India, Pvt. Ltd 01.03.2024; Elsevier
• Subjects: Acute coronary syndrome; Acute Coronary Syndrome - therapy; Angioplasty, Balloon, Coronary - methods; Female; Follow-Up Studies; Humans; Incidence; India - epidemiology; Male; Middle Aged; Percutaneous Coronary Intervention - methods; Platelet Aggregation Inhibitors - therapeutic use; Prasugrel; Prasugrel Hydrochloride - therapeutic use; Propensity Score; Purinergic P2Y Receptor Antagonists - administration & dosage; Purinergic P2Y Receptor Antagonists - adverse effects; Purinergic P2Y Receptor Antagonists - therapeutic use; Research Brief; Retrospective Studies; Ticagrelor; Ticagrelor - therapeutic use; Treatment Outcome; India; Prasugrel; Ticagrelor; Acute coronary syndrome
• ISSN: 0019-4832; 2213-3763
• DOI: 10.1016/j.ihj.2024.03.001

Evidence on comparative effectiveness and safety of prasugrel and ticagrelor post-percutaneous transluminal coronary angioplasty is scarce in Indian population. In a 1:1 propensity score-matched cohort with 71 individuals in each group, the incidence of a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or coronary revascularization was not significantly different in prasugrel and ticagrelor group (7.04% vs 9.86%; absolute difference, 2.8%; HR, 0.65; 95% CI, 0.21–2.1; p = 0.49). There was no significant difference in bleeding (5.63% vs 9.86%; absolute difference, −4.20%; 95% CI, −13.0%–4.5%) and dyspnea (7.04% vs 12.7%; absolute difference, −5.60%; 95% CI, −15.4%–4.1%).